Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Nurix Therapeutics (NRIX) Income from Continuing Operations: 2019-2024

Historic Income from Continuing Operations for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to -$193.6 million.

  • Nurix Therapeutics' Income from Continuing Operations fell 76.53% to -$86.4 million in Q3 2025 from the same period last year, while for Aug 2025 it was -$244.8 million, marking a year-over-year decrease of 38.32%. This contributed to the annual value of -$193.6 million for FY2024, which is 34.47% down from last year.
  • Latest data reveals that Nurix Therapeutics reported Income from Continuing Operations of -$193.6 million as of FY2024, which was down 34.47% from -$143.9 million recorded in FY2023.
  • Over the past 5 years, Nurix Therapeutics' Income from Continuing Operations peaked at -$43.2 million during FY2020, and registered a low of -$193.6 million during FY2024.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$180.4 million (2022), whereas its average is -$172.6 million.
  • In the last 5 years, Nurix Therapeutics' Income from Continuing Operations crashed by 171.28% in 2021 and then grew by 20.19% in 2023.
  • Yearly analysis of 5 years shows Nurix Therapeutics' Income from Continuing Operations stood at -$43.2 million in 2020, then plummeted by 171.28% to -$117.2 million in 2021, then plummeted by 53.90% to -$180.4 million in 2022, then increased by 20.19% to -$143.9 million in 2023, then crashed by 34.47% to -$193.6 million in 2024.